Published in Value Health on June 30, 2010
How contexts and issues influence the use of policy-relevant research syntheses: a critical interpretive synthesis. Milbank Q (2013) 1.25
Health technology assessment and its role in the future development of the Indian healthcare sector. Perspect Clin Res (2012) 1.11
Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts. BMC Med (2013) 1.00
Supporting local planning and budgeting for maternal, neonatal and child health in the Philippines. Health Res Policy Syst (2013) 0.89
Methodological variation in economic evaluations conducted in low- and middle-income countries: information for reference case development. PLoS One (2015) 0.88
Do economic evaluation studies inform effective healthcare resource allocation in Iran? A critical review of the literature. Cost Eff Resour Alloc (2014) 0.82
The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh. Health Res Policy Syst (2016) 0.75
Quality use of medicine in a developing economy: Measures to overcome challenges in the Malaysian healthcare system. SAGE Open Med (2015) 0.75
Health economic evaluations of medical devices in the People's Republic of China: A systematic literature review. Clinicoecon Outcomes Res (2015) 0.75
Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet (2009) 16.12
Multicriteria decision analysis for including health interventions in the universal health coverage benefit package in Thailand. Value Health (2012) 1.35
Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program. Pharmacoeconomics (2009) 1.23
Scaling up health policies and services in low- and middle-income settings. BMC Health Serv Res (2010) 1.22
Risk prediction models of breast cancer: a systematic review of model performances. Breast Cancer Res Treat (2011) 1.20
Criteria for priority setting of HIV/AIDS interventions in Thailand: a discrete choice experiment. BMC Health Serv Res (2010) 1.18
The economic impact of alcohol consumption: a systematic review. Subst Abuse Treat Prev Policy (2009) 1.17
Scaling up cervical cancer screening in the midst of human papillomavirus vaccination advocacy in Thailand. BMC Health Serv Res (2010) 1.12
Systematic review of economic evaluations of preparedness strategies and interventions against influenza pandemics. PLoS One (2012) 1.11
Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics (2011) 1.11
Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Epilepsia (2013) 1.07
Universal coverage and its impact on reproductive health services in Thailand. Reprod Health Matters (2002) 1.07
Universal coverage of renal dialysis in Thailand: promise, progress, and prospects. BMJ (2013) 1.06
Multi-criteria decision analysis for setting priorities on HIV/AIDS interventions in Thailand. Health Res Policy Syst (2012) 1.04
Health related quality of life among patients with tuberculosis and HIV in Thailand. PLoS One (2012) 1.02
Reviewing the evidence on effectiveness and cost-effectiveness of HIV prevention strategies in Thailand. BMC Public Health (2010) 0.99
Health-care systems and pharmacoeconomic research in Asia-Pacific region. Value Health (2008) 0.98
Using health technology assessment for informing coverage decisions in Thailand. J Comp Eff Res (2012) 0.97
Historical development of health technology assessment in Thailand. Int J Technol Assess Health Care (2009) 0.97
Impact of the introduction of government use licenses on the drug expenditure on seven medicines in Thailand. Value Health (2012) 0.97
A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. BMC Health Serv Res (2010) 0.94
Government use licenses in Thailand: an assessment of the health and economic impacts. Global Health (2011) 0.90
Social values and health policy: a new international research programme. J Health Organ Manag (2012) 0.90
Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health (2013) 0.89
Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand. BMC Public Health (2011) 0.87
Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Vaccine (2013) 0.86
The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand. J Med Assoc Thai (2008) 0.86
Health sector regulation in Thailand: recent progress and the future agenda. Health Policy (2003) 0.85
Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res (2013) 0.85
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. BMC Health Serv Res (2014) 0.85
The economic costs of alcohol consumption in Thailand, 2006. BMC Public Health (2010) 0.84
Variation of health-related quality of life assessed by caregivers and patients affected by severe childhood infections. BMC Pediatr (2013) 0.84
Mortality attributable to seasonal influenza A and B infections in Thailand, 2005-2009: a longitudinal study. Am J Epidemiol (2015) 0.83
Efficiency or equity: value judgments in coverage decisions in Thailand. J Health Organ Manag (2012) 0.83
Economic costs of obesity in Thailand: a retrospective cost-of-illness study. BMC Health Serv Res (2014) 0.82
Making health technology assessment information available for decision making: the development of a Thai database. J Med Assoc Thai (2008) 0.81
Economic impact on health-care costs related to major diseases including HIV/AIDS due to alcohol drinking among Thai populations. Value Health (2010) 0.80
Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense in Thailand: analysis of the effect of TRIPs-Plus proposal. Health Policy (2009) 0.80
A cost-utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand. Rheumatology (Oxford) (2013) 0.79
The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package. Clinicoecon Outcomes Res (2012) 0.78
Social and ethical analysis in health technology assessment. J Med Assoc Thai (2014) 0.77
Economic evaluation of treatment administration strategies of ganciclovir for cytomegalovirus retinitis in HIV/AIDS patients in Thailand: a simulation study. Pharmacoeconomics (2007) 0.77
Development and validation of a breast cancer risk prediction model for Thai women: a cross-sectional study. Asian Pac J Cancer Prev (2014) 0.77
The current capacity and future development of economic evaluation for policy decision-making: a survey among researchers and decision-makers in Thailand. Value Health (2010) 0.77
Lessons drawn from research utilization in the maternal iodine supplementation policy development in Thailand. BMC Public Health (2012) 0.77
Advanced health biotechnologies in Thailand: redefining policy directions. J Transl Med (2013) 0.75
Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics (2011) 0.75
The economic evaluation of medical devices: challenges. J Med Assoc Thai (2014) 0.75
A determination of topics for health technology assessment in Thailand: making decision makers involved. J Med Assoc Thai (2008) 0.75
National Health Insurance in South Africa: Relevance of a national priority-setting agency. S Afr Med J (2015) 0.75
Assessing key model parameters for economic evaluation of pandemic influenza interventions: the data source matters. Influenza Other Respir Viruses (2013) 0.75
Cost-utility analysis of recombinant human erythropoietin in anemic cancer patients induced by chemotherapy in Thailand. J Med Assoc Thai (2008) 0.75
Presentation of economic evaluation results. J Med Assoc Thai (2008) 0.75
Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis. Value Health (2012) 0.75
Health financing lessons from Thailand for South Africa on the path towards universal health coverage. S Afr Med J (2016) 0.75
Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand. Expert Rev Pharmacoecon Outcomes Res (2014) 0.75